Grifols (GRFS)
(Delayed Data from NSDQ)
$8.84 USD
+0.01 (0.11%)
Updated Oct 2, 2024 04:00 PM ET
Pre-Market: $8.81 -0.03 (-0.34%) 8:52 AM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.84 USD
+0.01 (0.11%)
Updated Oct 2, 2024 04:00 PM ET
Pre-Market: $8.81 -0.03 (-0.34%) 8:52 AM ET
3-Hold of 5 3
B Value D Growth F Momentum D VGM
Zacks News
Actinium Treats First Patient in AML Study on Actimab-A Combo
by Zacks Equity Research
Actinium (ATNM) treats first patient in the third and final cohort of the Actimab-A and CLAG-M combination phase I study to treat relapsed or refractory acute myeloid leukemia.
Grifols (GRFS) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Grifols (GRFS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for March 5th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:
GRFS or IONS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GRFS vs. IONS: Which Stock Is the Better Value Option?
Company News for Jul 8, 2019
by Zacks Equity Research
Companies In The News Are: OASM,GOL,GRFS,DELL
GRFS or ORINY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GRFS vs. ORINY: Which Stock Is the Better Value Option?
Grifols (GRFS) Surges: Stock Moves 5.4% Higher
by Zacks Equity Research
Grifols (GRFS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Is Grifols, S.A. (GRFS) a Great Stock for Value Investors?
by Zacks Equity Research
Is Grifols, S.A. (GRFS) a great pick from the value investor's perspective right now? Read on to know more.
Henry Schien to Distribute Grifols Product in United States
by Zacks Equity Research
We expect Henry Schien's (HSIC) partnership with Grifols to be strategically accretive to its portfolio given the rising demand for saline products in U.S. market.
Should Value Investors Consider Grifols (GRFS) Stock Now?
by Zacks Equity Research
Is Grifols (GRFS) a great pick from the value investor's perspective right now? Read on to know more.
Should Value Investors Consider Grifols (GRFS) Stock Right Now?
by Zacks Equity Research
Is Grifols a great pick from the value investor's perspective right now? Read on to know more.
VIVUS (VVUS) Loss Narrower than Expected, Revenues Up Y/Y
by Zacks Equity Research
VIVUS Inc. (VVUS) reported a loss of 1 cent per share in the first quarter of 2017, which was narrower than a loss of 12 cents in the year-ago period as well as the Zacks Consensus Estimate of a loss of 13 cents
Akebia Therapeutics (AKBA) Shows Strength: Stock Up 5.8%
by Zacks Equity Research
Akebia Therapeutics, Inc. (AKBA) shares rose almost 6% in the last trading session.
Glaxo (GSK) Reports In-Line Q1 Earnings, Reiterates View
by Zacks Equity Research
GlaxoSmithKline plc's (GSK) first quarter results came roughly in line with expectations. Glaxo reported first-quarter 2017 core earnings of 62 cents per American Depositary Share (ADS), in line with the Zacks Consensus Estimate.
Celgene (CELG) Tops on Q1 Earnings, Sales Miss, Raises View
by Zacks Equity Research
Celgene's (CELG) first-quarter results were mixed, with the company beating on earnings but missing on sales.
AbbVie (ABBV) Presents Positive Data on HCV Combination Drug
by Zacks Equity Research
AbbVie Inc. (ABBV) announced that data from two phase III studies, EXPEDITION-1 and ENDURANCE-3, evaluating its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P) for all genotypes of Hepatitis C virus (HCV)
Nivalis' (NVLS) Shares Down After Merger Deal with Alpine
by Zacks Equity Research
The announcement of Nivalis Therapeutics, Inc.'s (NVLS) merger agreement with a privately-held biotechnology company, Alpine Immune Sciences, Inc. failed to excite investors.
Zacks.com featured highlights: Arbor Realty, Commercial Vehicle Group, Grifols, S.A., Match Group and Xcerra
by Zacks Equity Research
Zacks.com featured highlights: Arbor Realty, Commercial Vehicle Group, Grifols, S.A., Match Group and Xcerra
GENOCEA BIOSCIENCES (GNCA) Catches Eye: Stock Gains 7.1%
by Zacks Equity Research
GENOCEA BIOSCIENCES, INC. (GNCA) moved big last session, as its shares rose over 7% on the day.
How to Uncover Institutional Buying
by Kevin Matras
Kevin Matras goes over how to screen for weekly volume increases to uncover institutional buying. Highlighted stocks include ABR, CVGI, GRFS, MTCH and XCRA.
AMAG Files for FDA Approval of Subcutaneous Form of Makena
by Zacks Equity Research
AMAG Pharmaceuticals, Inc. (AMAG) announced the submission of a supplemental New Drug Application (sNDA) to the FDA for the subcutaneous auto-injector form of its marketed drug Makena in the U.S.
Ohr Pharmaceutical (OHRP) Jumps: Stock Adds 15% in Session
by Zacks Equity Research
Ohr Pharmaceutical, Inc. (OHRP) moved big last session, as its shares jumped 15% on the day.
Infinity Pharmaceuticals (INFI) Looks Good: Stock Jumps 19%
by Zacks Equity Research
Infinity Pharmaceuticals, Inc. (INFI) shares rose over 19% in the last trading session.
TherapeuticsMD Falls on Likely Delay in TX-004HR Approval
by Zacks Equity Research
Shares of TherapeuticsMD, Inc. (TXMD) have declined almost 25% since Monday when it received a letter from the FDA identifying deficiencies in the new drug application (NDA) for its dyspareunia drug, TX-400HR filed last July
Galectin Therapeutics (GALT) Looks Good: Stock Jumps 16.7%
by Zacks Equity Research
Galectin Therapeutics, Inc. (GALT) shares rose nearly 17% in the last trading session.